How Altria's Q2 Results and Guidance Shape Its 2026 Earnings Path

Philip Morris International (PMI) and Altria have signed contract manufacturing deals to boost exports and imports. Altria will benefit from a tax rebate, while PMI maintains no U.S. sales plans. First shipments are expected in 2027, with no impact on 2026 performance. Altria expects a profit boost in late 2026 from similar partnerships.

Philip Morris International and Altria have signed contract manufacturing deals to boost cigarette imports and exports. Altria will benefit from a U.S. tax rebate, while PMI maintains no U.S. sales plans. First shipments are expected in 2027, with no 2026 performance impact. Altria expects a 2026 profit boost from similar partnerships.

Denver sued nine tobacco manufacturers and one distributor in state court, seeking compensation for cleanup and “continuing harms” from cigarette butt litter, citing non-biodegradable filters. The complaint names Philip Morris USA, Altria, R.J. Reynolds, Reynolds American, British American Tobacco and others, alleging littering is a foreseeable consequence of product design and marketing.

Altria Group (MO) reported Q2 adjusted EPS of $1.48, below the $1.50 expected, on net revenue of about $6.11B. Net earnings fell 3.4% to $2.3B. Marlboro volume dropped 7.4% and On! fell 4.2%, leading Altria to narrow FY adjusted EPS guidance to $5.61-$5.72. The article cites a $74 valuation target and 6.5% dividend yield.

The U.S. FDA authorized marketing of four new flavored nicotine pouch products from brand “on!” and raised the total recently approved to 30. The FDA also previously cleared ZYN for 20 products with a “Modified Risk Tobacco Product” claim. Philip Morris makes ZYN and Altria makes “on!”. Health groups cite youth use and addiction risks; FDA says MRTP status does not mean risk-free.

The FDA authorized marketing of four On Plus nicotine pouch products made by Helix Innovations, a subsidiary of Altria. The FDA said the review was under a September pilot program and that the pouches have lower levels of most harmful and potentially harmful constituents versus other oral and smokeless products. Altria reported first-half 2026 net revenues up 1.6% to $11.5 billion.